News

News
VitaDX
May «Bladder Cancer Awareness Month»
31 May 2022 -

On this last day of May «Bladder Cancer Awareness Month», the entire VitaDX team reiterates its support to patients by working every day to…

santé expo
SANTEXPO 2022
17 May 2022 -

VitaDX was present at SANTEXPO 2022 to attend the Workshop "How to accelerate to Europe?"

conf
First public conference dedicated to bladder cancer, organized by the University Hospital of Rennes and the Eugène Marquis Center
12 May 2022 -

VitaDX attended the first public conference dedicated to bladder cancer, organized by the University Hospital of Rennes and the Eugène Marquis…

rennes business
Interview with Allan Rodrigues - CEO of VitaDX by Destination Rennes Business
25 April 2022 -

Allan Rodriguez - CEO of VitaDX was interviewed by Destination Rennes to present the startup VitaDX and its in vitro diagnostic medical device…

ouest france
An article from Ouest France: A breton artificial intelligence to detect bladder cancer
30 November 2021 -

Thanks to Ouest France for this very nice article.
VitaDX has been partnering for several years with LTSI  (Signal and Image Processing…

ECOSYSTEME
ECOSYSTEME - Interview of Allan Rodriguez and Dr Camélia Radulescu on B SMART
20 September 2021 -

Thomas Hugues welcomes Allan Rodriguez (VitaDX) and Camélia Radulescu (Foch hospital) to ÉCOSYSTÈME to talk about VitaDX's new diagnostic solution…

VitaDX
4th round of financing for VitaDX
21 September 2020 -

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

VisioCyt
CE marking of the VisioCyt® solution
11 February 2020 -

VitaDX is very proud to announce the CE marking of its first software solution dedicated to bladder cancer diagnosis: VisioCyt®.

VitaDX, Go Capital, Odyssee Venture et Auriga
VitaDX raises €4 million from GO CAPITAL, AURIGA Partners, ODYSSEE Venture and FFBB Management
9 July 2019 -

This fundraising will allow VitaDX to finalize the development and ensure the commercial deployment of its first early bladder cancer detection…